Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer.
Research output: Contribution to journal › Article
Breast cancer (BC) is one of the leading causes of death among women worldwide. Immunostimulatory treatment has increasingly been used as adjuvant therapy in the last few years, in patients with melanoma and other cancer forms, often with an induction of autoimmunity as a consequence of a successful treatment. We aimed at investigating if coexisting autoimmune diseases (AD) or hypersensitivities (HS) similarly to the side effects of immunostimulatory treatment resulted in a better overall survival, compared to patients without these disorders.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Publication status||Published - 2013|
No data available